Trade Leads

Pine Pharmaceuticals Pioglitazone and Placebo The major goal of the proposed research is to assess the effects of the PPAR-y agonist pioglitazone in SLE on vascular function and inflammation and on SLE disease activity. Pioglitazone and placebo capsules are required to perform approved clinical trial on the role of Pioglitazone in lupus. The drug and placebo will be administered to patients in an ongoing clinical trial. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified business sources; and (2) their size classification relative to the North American Industry Classification System (NAICS) code 325411 for the proposed acquisition. Your responses to the information requested will assist the Government in determining the appropriate acquisition method. All capability Statements sent in response to this SOURCES SOUGHT notice must be submitted electronically to Arun Mathur, Contract Specialist, at in either MS Word or Adobe Portable Document Format (PDF), by July 12th, 2016, 9:00 AM, EASTERN TIME under Solicitation Number: HHS-NIH-NHLBI-CSB-DE-2016-202-AKM. FAXES ARE NOT ACCEPTED Contracting Office Address: Office of Acquisitions 6701 Rockledge Dr RKL2/6100 MSC 7902 Bethesda, Maryland 20892-7902 Primary Point of Contact.: Arun K. Mathur, Contract Specialist Phone: 3014518045 Secondary Point of Contact: Lisa Portner, Contracting Officer Phone: 3014350326